<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Until the mid 1960s the advanced stage, high grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo>, fatal diseases with few patients remaining alive at 5 years </plain></SENT>
<SENT sid="1" pm="."><plain>Studies conducted at the NCI demonstrated that 47% of <z:hpo ids='HP_0000001'>all</z:hpo> patients with advanced stages of diffuse mixed, large cell, and undifferentiated non-Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> could achieve a complete remission documented by reevaluation of <z:hpo ids='HP_0000001'>all</z:hpo> initially involved sites following treatment with either the C-MOPP or BACOP combination chemotherapy regimens </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, 70% to 80% of these complete responders had long-term disease-free survival tan-tamount to cure </plain></SENT>
<SENT sid="3" pm="."><plain>The third generation of NCI studies, termed the ProMACE-MOPP flexible induction program, significantly improved these results </plain></SENT>
<SENT sid="4" pm="."><plain>Complete remissions were achieved in 74% of <z:hpo ids='HP_0000001'>all</z:hpo> patients and 73% of these remain disease free in excess of 3 years </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> was dose limiting with a 10% septic <z:hpo ids='HP_0011420'>death</z:hpo> rate </plain></SENT>
<SENT sid="6" pm="."><plain>Studies are currently underway in an attempt to minimize the toxicity of the new regimen, while preserving the increased complete response rates and long-term survival </plain></SENT>
</text></document>